ClinicalTrials.gg
CompletedNCT07221955Updated Oct 5, 2026

The Impact of Qualia Gluthathione+ on Blood Glutathione Levels

An interventional study of Qualia Glutathione+ version 1 and Qualia Glutathione+ version 2 in Effects of Qualia Glutathione+ on Blood Glutathione Levels and Glutathione, sponsored by Qualia Life Sciences. Completed at 1 site in United States. Open to participants aged 45 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Qualia Life Sciences · Not applicable, Interventional, and Other

Updated Oct 5, 2026Now CompletedStart date moved+2 moreGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
56
Allocation
Non-randomized
Ages
45 Years to 75 Years
Sex
All
01

Study summary

This is a double-blind, placebo-controlled, parallel-group, triple-armed, study evaluating the effects of two distinct Qualia Glutathione+ formulations on Whole Blood Glutathione levels in the blood of healthy adults aged 45-75 years. Approximately 18 participants will be assigned to one of three study arms: Qualia Glutathione+ version 1, Qualia Glutathione+ version 2, or placebo. Each participant will take two or three capsules of their assigned product once daily in the morning, with or without food, over a 20-day period. The primary outcome is the change in blood glutathione levels, assessed via in lab blood collection at baseline and study completion. Secondary endpoints include questionnaires measuring health-related quality of life, fatigue, and cognitive functioning (PROMIS Global Health-10, PROMIS Short Form v1.0 - Fatigue 10a, PROMIS Cognitive Function - Short Form 8a), evaluation of safety and tolerability, and an Overall Experience Questionnaire (Appendices 1, 4-7). All assessments, including electronic questionnaires, are completed remotely without in-person visits.

Read the detailed description

Note on allocation (added September 2026): Participants were assigned to study arms by systematic allocation rather than by random allocation. Earlier versions of this record described the design as randomized. The Allocation field and the design descriptions were corrected to Non-Randomized to reflect the method actually used. No other aspect of the study design, conduct, or analysis changed.

02

Conditions studied

  • Effects of Qualia Glutathione+ on Blood Glutathione Levels
  • Glutathione
03

In context

Lead sponsor

Qualia Life Sciences is the lead sponsor of 14 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provide voluntary, written, to participate in the study
  • Agree to provide a valid cell phone number and are willing to receive communications through text
  • Can read and write English
  • Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly
  • Willing to complete questionnaires, records, and diaries associated with the study.
  • Healthy male and female participants aged 45-75 years
  • Willing to go to a local blood draw location for a Whole Blood Total Glutathione measurement (baseline and Day 20)
  • Willing to avoid starting new or stopping any existing dietary supplements throughout the study

Exclusion criteria

Exclusion criteria:

  • Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
  • Known food intolerances/allergy to any ingredients in the product
  • Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
  • Having had a significant cardiovascular event in the past 6 months
  • Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
  • On therapy
  • Adults lacking capacity to consent
  • Active Smokers
  • Diagnosed Diabetics
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Active comparator
    Qualia Glutathione+ version 1

    Qualia Glutathione+ version 1 manufactured by Qualia Life Sciences

    Dietary Supplement: Qualia Glutathione+ version 1

  • Active comparator
    Qualia Glutathione+ version 2

    Qualia Glutathione+ version 2 manufactured by Qualia Life Sciences

    Dietary Supplement: Qualia Glutathione+ version 2

  • Placebo comparator
    Placebo

    Rice flour placebo

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementQualia Glutathione+ version 1

    Qualia Glutathione+ version 1 manufactured by Qualia Life Sciences

  • Dietary supplementQualia Glutathione+ version 2

    Qualia Glutathione+ version 2 manufactured by Qualia Life Sciences

  • Dietary supplementPlacebo

    Rice flour

06

What researchers measure

Primary outcomes

  1. Total Glutathione levels from baseline to Day 20

    To assess between-group differences in the change in blood Total Glutathione levels from baseline to Day 20 following supplementation with Qualia Glutathione version 1 versus placebo and Qualia Glutathione version 2 versus placebo

    Time frame: 0-20 days

Secondary outcomes

  1. between-group differences in blood Total Glutathione levels

    To assess the between-group differences in blood Total Glutathione levels from baseline to Day 20 following supplementation between Qualia Glutathione version 1 and Qualia Glutathione version 2.

    Time frame: baseline to day 20

  2. within-group differences in the change in blood Glutathione levels

    To assess within-group differences in the change in blood Glutathione levels

    Time frame: baseline to day 20

  3. Safety and Tolerability survey

    To evaluate side effect profiles using a custom Safety and Tolerability survey.

    Time frame: baseline to days 7, 14 and 20

  4. PROMIS Global Health-10

    The PROMIS® Global Health Scale v1.2 (also known as the PROMIS-GH or PROMIS-10) is a 10-item, non-disease-specific questionnaire for adults to assess general physical and mental health. It yields two main scores, a Global Physical Health (GPH) T-score and a Global Mental Health (GMH) T-score, derived from four items each, to understand overall health perceptions. The scale is widely translated and free for use in clinical and research settings. * Raw Score Minimum and Maximum: 0-20 * The higher the score, the better

    Time frame: baseline to days 7, 14 and 20

  5. PROMIS Short Form v1.0 - Fatigue 10a

    The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The fatigue short forms are universal rather than disease-specific. All assess fatigue over the past seven days. Raw Score Minimum and Maximum: 10-50 the lower the better

    Time frame: baseline to days 7, 14 and 20

  6. PROMIS Cognitive Function - Short Form 8a

    The PROMIS Cognitive Function v2.0 - Short Form 8a is an 8-item self-report questionnaire designed to assess perceived cognitive function over the past seven days. It measures difficulties in areas such as forming thoughts, concentration, attention, thinking speed, memory, and the ability to shift between tasks. \- Raw Score Minimum and Maximum: 8-40 - The higher the score, the better

    Time frame: baseline to days 7, 14 and 20

07

Study locations

1 site
  • Qualia Life Sciences
    Carlsbad, California 92011, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2025 to primary completion in Dec 2025, 0 months.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Nov 2025, on Oct 5, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2025
First posted
Oct 29, 2025
StartActual
Nov 30, 2025was Dec 2025
Primary completionActual
Dec 22, 2025
CompletionActual
Jan 8, 2026
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 5, 2026
Start date
Dec 2, 2025→Nov 30, 2025 (actual)
Oct 5, 2026
Study completion
Jan 25, 2026→Jan 8, 2026 (actual)
Oct 5, 2026
Enrollment
54 (estimated)→56 (actual)
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    Not yet recruiting→Completed
    Start date Dec 2, 2025→Nov 30, 2025 (now actual)
    Study completion Jan 25, 2026→Jan 8, 2026 (now actual)
    Enrollment 54 (estimated)→56 (actual)
    + 4 other changes: verification date, description, design details and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07221955
Responsible party
Sponsor
First posted
Oct 29, 2025
Start date
Nov 30, 2025
Primary completion
Dec 22, 2025
Completion
Jan 8, 2026
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion